CPRX - Catalyst Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Catalyst Pharmaceuticals, Inc.

355 Alhambra Circle
Suite 1250
Coral Gables, FL 33134
United States
305-420-3200
http://www.catalystpharma.com

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees21

Key Executives

NameTitlePayExercisedYear Born
Mr. Patrick J. McEnanyCo-Founder, Chairman, Chief Exec. Officer and Pres496.56kN/A1947
Ms. Alicia Grande CPA, CMAChief Financial Officer, Chief Accounting Officer, VP and Treasurer326.6kN/A1971
Dr. Steven R. Miller Ph.D.Chief Operating Officer and Chief Scientific Officer394.2kN/A1962
Dr. Gary Ingenito M.D., Ph.D.Chief Medical Officer and Head of Regulatory Affairs375.83kN/A1956
Mr. Brian ElsberndSr. VP of Legal and ComplianceN/AN/A1964
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3. The company is also developing CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor for the treatment of refractory infantile spasms; and CPP-109, a vigabatrin tablet. It has license agreements with Northwestern University, New York University and the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Corporate Governance

Catalyst Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 6. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 8; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.